(-0.13%) 5 462.19 points
(-0.35%) 38 975 points
(0.26%) 17 763 points
(0.35%) $81.11
(-3.48%) $2.66
(-0.97%) $2 308.10
(-0.43%) $28.75
(1.53%) $1 001.50
(0.27%) $0.936
(0.85%) $10.69
(0.37%) $0.791
(-0.16%) $87.35
Live Chart Being Loaded With Signals
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation...
Stats | |
---|---|
本日の出来高 | 0 |
平均出来高 | 0 |
時価総額 | 0.00 |
EPS | $-0.0757 ( Q2 | 2022-06-30 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
JUPITER NEUROSCIENCES, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
JUPITER NEUROSCIENCES, 財務諸表
Annual | 2021 |
収益: | $638 037 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.443 |
FY | 2021 |
収益: | $638 037 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.443 |
FY | 2020 |
収益: | $1.13M |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.189 |
FY | 2019 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.349 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
JUPITER NEUROSCIENCES,
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich\'s Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer\'s disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。